Literature DB >> 27025939

Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.

Liesbet De Bus1, Wouter Denys2, Julie Catteeuw2, Bram Gadeyne2, Karel Vermeulen3, Jerina Boelens4, Geert Claeys4, Jan J De Waele2, Johan Decruyenaere2, Pieter O Depuydt2,5.   

Abstract

PURPOSE: Antibiotic de-escalation is promoted to limit prolonged exposure to broad-spectrum antibiotics, but proof that it prevents the emergence of resistance is lacking. We evaluated determinants of antibiotic de-escalation in an attempt to assess whether the latter is associated with a lower emergence of antimicrobial resistance.
METHODS: Antibiotic treatments, starting with empirical beta-lactam prescriptions, were prospectively documented during 2013 and 2014 in a tertiary intensive care unit (ICU) and categorized as continuation, de-escalation or escalation of the empirical antimicrobial treatment. Determinants of the de-escalation or escalation treatments were identified by multivariate logistic regression; the continuation category was used as the reference group. Using systematically collected diagnostic and surveillance cultures, we estimated the cumulative incidence of antimicrobial resistance following de-escalation or continuation of therapy, with adjustment for ICU discharge and death as competing risks.
RESULTS: Of 478 anti-pseudomonal antibiotic prescriptions, 42 (9 %) were classified as escalation of the antimicrobial treatment and 121 (25 %) were classified as de-escalation, mainly through replacement of the originally prescribed antibiotics with those having a narrower spectrum. In multivariate analysis, de-escalation was associated with the identification of etiologic pathogens (p < 0.001). The duration of the antibiotic course in the ICU in de-escalated versus continued prescriptions was 8 (range 6-10) versus 5 (range 4-7) days, respectively (p < 0.001). Mortality did not differ between patients in the de-escalation and continuation categories. The cumulative incidence estimates of the emergence of resistance to the initial beta-lactam antibiotic on day 14 were 30.6 and 23.5 % for de-escalation and continuation, respectively (p = 0.22). For the selection of multi-drug resistant pathogens, these values were 23.5 (de-escalation) and 18.6 % (continuation) respectively (p = 0.35).
CONCLUSION: The emergence of antibiotic-resistant bacteria after exposure to anti-pseudomonal beta-lactam antibiotics was not lower following de-escalation.

Entities:  

Keywords:  Antibiotic stewardship; Beta-lactam antibiotics; De-escalation; Information technology system; Multi-drug resistance

Mesh:

Substances:

Year:  2016        PMID: 27025939     DOI: 10.1007/s00134-016-4301-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  28 in total

Review 1.  Hospital-acquired pneumonia and de-escalation of antimicrobial treatment.

Authors:  M H Kollef
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

Review 3.  Antibiotic de-escalation in the ICU: how is it best done?

Authors:  Jose Garnacho-Montero; Ana Escoresca-Ortega; Esperanza Fernández-Delgado
Journal:  Curr Opin Infect Dis       Date:  2015-04       Impact factor: 4.915

Review 4.  Not in my backyard: a systematic review of clinicians' knowledge and beliefs about antibiotic resistance.

Authors:  A R McCullough; J Rathbone; S Parekh; T C Hoffmann; C B Del Mar
Journal:  J Antimicrob Chemother       Date:  2015-06-20       Impact factor: 5.790

5.  A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients.

Authors:  Mieke Carlier; Jason A Roberts; Veronique Stove; Alain G Verstraete; Jeffrey Lipman; Jan J De Waele
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

6.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

7.  De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.

Authors:  Djamel Mokart; Géraldine Slehofer; Jérôme Lambert; Antoine Sannini; Laurent Chow-Chine; Jean-Paul Brun; Pierre Berger; Ségolène Duran; Marion Faucher; Jean-Louis Blache; Colombe Saillard; Norbert Vey; Marc Leone
Journal:  Intensive Care Med       Date:  2014-01       Impact factor: 17.440

8.  De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?

Authors:  Jan J De Waele; Mariska Ravyts; Pieter Depuydt; Stijn I Blot; Johan Decruyenaere; Dirk Vogelaers
Journal:  J Crit Care       Date:  2010-01-15       Impact factor: 3.425

9.  De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit.

Authors:  Jérôme Morel; Julie Casoetto; Richard Jospé; Gérald Aubert; Raphael Terrana; Alain Dumont; Serge Molliex; Christian Auboyer
Journal:  Crit Care       Date:  2010-12-17       Impact factor: 9.097

10.  Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis.

Authors:  Liesbet De Bus; Lies Saerens; Bram Gadeyne; Jerina Boelens; Geert Claeys; Jan J De Waele; Dominique D Benoit; Johan Decruyenaere; Pieter O Depuydt
Journal:  Crit Care       Date:  2014-07-15       Impact factor: 9.097

View more
  26 in total

1.  Antibiotic de-escalation: observational causal inference and culture dependence.

Authors:  Georgios D Kitsios; Alison Morris; Bryan J McVerry
Journal:  Intensive Care Med       Date:  2016-07-18       Impact factor: 17.440

2.  Infection management in patients with sepsis and septic shock in resource-limited settings: focus on appropriate antimicrobial.

Authors:  Ashraf Roshdy
Journal:  Intensive Care Med       Date:  2016-10-13       Impact factor: 17.440

3.  Antibiotic stewardship: do not rely on de-escalation alone.

Authors:  Liesbet De Bus; Pieter O Depuydt
Journal:  Intensive Care Med       Date:  2016-08-04       Impact factor: 17.440

Review 4.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

5.  Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP).

Authors:  Alexis Tabah; Matteo Bassetti; Marin H Kollef; Jean-Ralph Zahar; José-Artur Paiva; Jean-Francois Timsit; Jason A Roberts; Jeroen Schouten; Helen Giamarellou; Jordi Rello; Jan De Waele; Andrew F Shorr; Marc Leone; Garyphallia Poulakou; Pieter Depuydt; Jose Garnacho-Montero
Journal:  Intensive Care Med       Date:  2019-11-28       Impact factor: 17.440

Review 6.  What's new in multidrug-resistant pathogens in the ICU?

Authors:  Gabor Zilahi; Antonio Artigas; Ignacio Martin-Loeches
Journal:  Ann Intensive Care       Date:  2016-10-06       Impact factor: 6.925

7.  Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial.

Authors:  Luis Eduardo López-Cortés; Clara Rosso-Fernández; María Núñez-Núñez; Lucía Lavín-Alconero; José Bravo-Ferrer; Ángel Barriga; Mercedes Delgado; Carmen Lupión; Pilar Retamar; Jesús Rodríguez-Baño
Journal:  BMJ Open       Date:  2017-06-09       Impact factor: 2.692

8.  Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs.

Authors:  Josie Hughes; Xi Huo; Lindsey Falk; Amy Hurford; Kunquan Lan; Bryan Coburn; Andrew Morris; Jianhong Wu
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

9.  Predicting and managing sepsis in burn patients: current perspectives.

Authors:  Omar Nunez Lopez; Janos Cambiaso-Daniel; Ludwik K Branski; William B Norbury; David N Herndon
Journal:  Ther Clin Risk Manag       Date:  2017-08-29       Impact factor: 2.423

10.  Potential Adverse Effects of Broad-Spectrum Antimicrobial Exposure in the Intensive Care Unit.

Authors:  Jenna Wiens; Graham M Snyder; Samuel Finlayson; Monica V Mahoney; Leo Anthony Celi
Journal:  Open Forum Infect Dis       Date:  2017-12-19       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.